Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated May 29, 2020 (6 years ago)

amneal Metformin Hydrochloride Extended-release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

amneal Metformin Hydrochloride Extended-release Tablets, USP, 500 mg Rx Only, 500 Tablets bottles, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Ahmedabad 388213, INDIA Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 NDC 65162-178-50

Affected NDC 65162-0178-50

Compare with the code on your package — it is the most precise check available.

Drug: Metformin Category: Diabetes Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Metformin Hydrochloride
NDC 65162-0178
500 mg/1 Tablet, Extended Release
Oral
Amneal Pharmaceuticals LLC Rx
Recalling firm
Amneal Pharmaceuticals of New York, LLC
NDC code
65162-178-50
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1345-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Metformin recalls

See all
Class II · Moderate risk

Synjardy XR Tablets

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Ongoing cGMP deviation Boehringer Ingelheim Pharmaceuticals, Inc. D-0657-2026

Other recalls by Amneal Pharmaceuticals of New York, LLC

All 2020 recalls
Class II · Moderate risk

Exenatide Injection

Defective Delivery System: Possibility of no medication in the prefilled pen.

Ongoing Packaging defect Amneal Pharmaceuticals of New York, LLC NDC 70121-1685-1 D-0868-2026